An engineered human antibody to TNF (CDP571) for active Crohn's disease: A randomized double-blind placebo-controlled trial

• DOI: 10.1053/gast.2001.24042
• Publication Date: 2005-07-29T17:58:00Z
• Authors: William J. Sandborn; Brian G. Feagan; Stephen B. Hanauer; Daniel H. Present; Lloyd R. Sutherland; Michael A. Kamm; Douglas C. Wolf; Jeffrey P. Baker; Christopher Hawkey; Andre Archambault; Charles N. Bernstein; Claire Novak; Patricia K. Heath; Stephan R. Targan
• Keywords: Adult; Male; Adolescent; Dose-Response Relationship, Drug; Tumor Necrosis Factor-alpha; Antibodies, Monoclonal; Middle Aged; Infliximab; 3. Good health; 03 medical and health sciences; 0302 clinical medicine; Crohn Disease; Double-Blind Method; Humans; Female; Aged

We evaluated CDP571, a humanized antibody to tumor necrosis factor, for the treatment of active Crohn's disease.One hundred sixty-nine patients with moderate-to-severe Crohn's disease were enrolled in a 24-week placebo-controlled trial. Patients were initially randomized to a single dose of 10 or 20 mg/kg CDP571 or placebo to assess dose response. Patients were then retreated with 10 mg/kg CDP571 or placebo every 8 or 12 weeks to assess subsequent dosing intervals. The primary endpoint was clinical response at week 2, defined as a decrease in the Crohn's Disease Activity Index score > or = 70 points.At week 2, clinical response occurred in 45% of CDP571-treated patients compared with 27% of patients in the placebo group (P = 0.023). Patients appeared to benefit from retreatment with CDP571 over 24 weeks, but not all of the results for secondary endpoints were statistically significant. The frequency of severe or serious adverse events was similar among all groups.CDP571 at an initial dose of 10 or 20 mg/kg is safe and effective for treatment of patients with moderate-to-severe Crohn's disease. Preliminary evidence suggests that retreatment with 10 mg/kg CDP571 at dose intervals of 8 or 12 weeks may also be beneficial, but additional studies are needed.